Literature DB >> 17689818

Randomized trials or population-based registries.

D Bergqvist, M Björck, J Säwe, T Troëng.   

Abstract

Mesh：

Year:  2007        PMID： 17689818     DOI： 10.1016/j.ejvs.2007.06.014

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN： 1078-5884            Impact factor:   7.069


× No keyword cloud information.
  6 in total

1.  Monitoring the practice of vascular surgery: findings from a national registry (1996-2011).

Authors:  Francisco S Lozano; Josep Marinello; Rosa M Moreno; Maria D Aguilar; Alfonso López-Quintana; Jose R Gonzalez-Porras; Javier Alvarez; Antonio Giménez-Gaibar; Rafael Alguacil; Marc A Cairols; Miguel A Marco-Luque; Fernando Vaquero; José M Callejas
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

2.  Long-term Outcomes Associated With Open vs Endovascular Abdominal Aortic Aneurysm Repair in a Medicare-Matched Database.

Authors:  Kevin Yei; Asma Mathlouthi; Isaac Naazie; Nadin Elsayed; Bryan Clary; Mahmoud Malas
Journal:  JAMA Netw Open       Date:  2022-05-02

Review 3.  Defining key design elements of registry-based randomised controlled trials: a scoping review.

Authors:  Bill Karanatsios; Khic-Houy Prang; Ebony Verbunt; Justin M Yeung; Margaret Kelaher; Peter Gibbs
Journal:  Trials       Date:  2020-06-22       Impact factor: 2.279

4.  Improvements in esophageal and gastric cancer care in Sweden-population-based results 2007-2016 from a national quality register.

Authors:  M Jeremiasen; G Linder; J Hedberg; L Lundell; O Björ; M Lindblad; J Johansson
Journal:  Dis Esophagus       Date:  2020-03-16       Impact factor: 3.429

5.  Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry.

Authors:  Ajit Sood; Kirandeep Kaur; Ramit Mahajan; Vandana Midha; Arshdeep Singh; Sarit Sharma; Amarender Singh Puri; Bhabhadev Goswami; Devendra Desai; C Ganesh Pai; Kiran Peddi; Mathew Philip; Rakesh Kochhar; Sandeep Nijhawan; Shobna Bhatia; N Sridhara Rao
Journal:  Intest Res       Date:  2020-07-13

6.  Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.

Authors:  Andreas Schneeweiss; Johannes Ettl; Diana Lüftner; Matthias W Beckmann; Erik Belleville; Peter A Fasching; Tanja N Fehm; Matthias Geberth; Lothar Häberle; Peyman Hadji; Andreas D Hartkopf; Carsten Hielscher; Jens Huober; Eugen Ruckhäberle; Wolfgang Janni; Hans Christian Kolberg; Christian M Kurbacher; Evelyn Klein; Michael P Lux; Volkmar Müller; Naiba Nabieva; Friedrich Overkamp; Hans Tesch; Elena Laakmann; Florin-Andrei Taran; Julia Seitz; Christoph Thomssen; Michael Untch; Pauline Wimberger; Rachel Wuerstlein; Bernhard Volz; Diethelm Wallwiener; Markus Wallwiener; Sara Y Brucker
Journal:  Breast       Date:  2020-08-29       Impact factor: 4.380
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.